Biosuganril 5 mg (Serratiopeptidase)

Product Overview

Biosuganril 5 mg is a prescription‑strength oral formulation that contains the proteolytic enzyme serratiopeptidase. It is manufactured by Abbott India Pvt Ltd and supplied in strips of ten tablets. The medication is classified under the therapeutic class of pain‑relief agents and is specifically indicated for the management of acute and chronic inflammatory conditions accompanied by swelling. Each tablet delivers exactly 5 mg of the active enzyme, ensuring consistent systemic absorption. The product is packaged in a convenient strip that protects each tablet from moisture and contamination, making it suitable for patients who require a reliable dosing schedule. Biosuganril is available in pack sizes of 60, 90, and 120 tablets, allowing clinicians to tailor treatment duration to individual patient needs.

What is Biosuganril 5 mg

Biosuganril 5 mg belongs to a class of enzyme‑based therapeutics that work by hydrolyzing abnormal protein deposits at the site of injury. Serratiopeptidase, the active moiety, degrades fibrin and other fibrous tissues, thereby reducing localized edema and associated discomfort. Although the precise molecular target remains under investigation, clinical studies suggest that the enzyme modulates the inflammatory cascade by decreasing the concentration of pro‑inflammatory cytokines such as interleukin‑1β and tumor necrosis factor‑α. This mechanism positions Biosuganril as a viable option for patients seeking anti‑inflammatory support without the gastric irritation commonly associated with non‑steroidal anti‑inflammatory drugs (NSAIDs).

Uses and Benefits

The therapeutic utility of Biosuganril 5 mg extends to a variety of clinical scenarios where inflammation and swelling impair normal function. Physicians commonly prescribe it for postoperative recovery, tendonitis, bursitis, and acute musculoskeletal injuries. By attenuating edema, the medication can improve joint mobility and accelerate return to daily activities. In chronic conditions such as rheumatoid arthritis and osteoarthritis, Biosuganril may complement conventional analgesics, offering a steroid‑sparing effect that reduces reliance on high‑dose corticosteroids. Patients also report decreased tenderness in dental postoperative inflammation and certain dermatologic disorders characterized by localized swelling.

How It Works

The principal action of Biosuganril 5 mg is enzymatic degradation of extracellular matrix proteins that accumulate during the inflammatory response. Serratiopeptidase cleaves peptide bonds within fibrin, hyaluronic acid, and kininogen, leading to a reduction in viscous exudate and facilitating lymphatic drainage. This proteolysis indirectly lowers the concentration of prostaglandins and leukotrienes, which are mediators of pain and vasodilation. Consequently, nerve endings are exposed to fewer inflammatory stimuli, translating into a perceptible decline in tenderness. Pharmacokinetic data indicate that oral absorption is modest but sufficient to achieve therapeutic concentrations in synovial fluid, supporting its use in joint‑related pathologies.

Dosage Guidelines

Biosuganril 5 mg should be administered orally with a full glass of water, preferably on an empty stomach to optimize bioavailability. The standard adult dosage for the treatment of acute inflammatory conditions is one tablet two to three times daily, depending on the severity of symptoms and physician assessment. For chronic maintenance, a single daily dose may be sufficient once clinical improvement is observed. Pediatric use is not recommended unless specifically directed by a pediatric specialist, due to limited safety data in children under twelve years of age. Patients with hepatic impairment should reduce the dose to one tablet once daily, as reduced metabolism may increase systemic exposure.

Side Effects

Like all enzyme‑based therapies, Biosuganril 5 mg may elicit adverse reactions, although most are mild and self‑limiting. The most frequently reported side effects include gastrointestinal discomfort such as nausea, dyspepsia, and transient diarrhea. Allergic manifestations such as skin rash, pruritus, and occasional urticaria have also been documented in clinical trials. Rarely, patients may experience hypersensitivity responses that necessitate immediate discontinuation and medical evaluation. It is advisable for individuals with a known history of hypersensitivity to serratiopeptidase or any excipients to avoid use. Concomitant administration with other anti‑inflammatory agents should be monitored for additive gastrointestinal effects.

Warnings and Precautions

Prior to initiating therapy with Biosuganril 5 mg, clinicians should obtain a comprehensive medication history to identify potential drug interactions. Patients with active peptic ulcer disease or severe gastritis are advised to use the medication cautiously, as proteolytic activity may exacerbate mucosal irritation. Concurrent use of anticoagulants, aspirin, or other agents that affect platelet aggregation warrants careful monitoring, given the theoretical risk of increased bleeding tendency. Pregnant and lactating women should consult a healthcare professional before use, as adequate safety data in these populations are lacking. In the event of overdose, symptomatic treatment and medical supervision are recommended.

Frequently Asked Questions

Is Biosuganril 5 mg safe for long‑term use?

Clinical studies have evaluated Biosuganril 5 mg for periods up to twelve weeks, and longer‑term safety data remain limited. Physicians typically reassess the patient’s response after four to six weeks of treatment and may discontinue therapy if benefits do not persist. Chronic use should only be continued under medical supervision, with periodic monitoring of liver function and gastrointestinal symptoms. If you notice new or worsening side effects, contact your healthcare provider promptly.

Can Biosuganril be taken with NSAIDs?

Biosuganril 5 mg can be co‑administered with non‑steroidal anti‑inflammatory drugs (NSAIDs), but caution is advised because both agents may increase the risk of gastric irritation. Patients with a history of peptic ulcer disease should discuss combination therapy with their physician, who may recommend a proton‑pump inhibitor or an alternative anti‑inflammatory strategy. Always inform your doctor about all prescription and over‑the‑counter medications you are using.

What should I do if I miss a dose?

If you miss a scheduled dose, simply skip the forgotten tablet and resume your regular dosing schedule. Do not double the dose to compensate, as this may increase the likelihood of adverse effects. Maintaining a consistent dosing routine helps achieve steady enzyme levels in the bloodstream, which is important for optimal anti‑inflammatory activity. Setting a reminder or using a pill organizer can help prevent missed doses.

Are there any dietary restrictions while taking Biosuganril?

No specific dietary restrictions are required while taking Biosuganril 5 mg, although it is recommended to take the tablet on an empty stomach to enhance absorption. Avoid consuming large amounts of acidic beverages, such as citrus juices, immediately before or after the dose, as they may affect gastric pH and marginally reduce bioavailability. Staying well‑hydrated and maintaining a balanced diet rich in antioxidants can support overall recovery.

Where can I find more scientific information about serratiopeptidase?

Serratiopeptidase has been the subject of numerous peer‑reviewed studies indexed in PubMed and reviewed by the National Institutes of Health (NIH) for its anti‑inflammatory properties. For detailed scientific literature, you may visit the NIH’s PubMed database (PubMed) or the Drugs.com reference page on serratiopeptidase (Drugs.com). These resources provide access to clinical trial results, mechanism‑of‑action analyses, and safety profiles.

Related Products

• PPG 0.3 mg (Voglibose)
• Brufen 200 mg (Ibuprofen)
• Tyza Cream (Terbinafine)
• Melalite Forte Cream (Hydroquinone)
• Claribid 250 mg (Clarithromycin)
• Claribid (Clarithromycin)
• Claribid 500 mg (Clarithromycin)
• Pentids (Penicillin G)
• Pentids 400 (Penicillin G)
• Pentids 800 Tablet (Penicillin G)
• Kenacort Injection (Triamcinolone )
• Brufen 400 mg (Ibuprofen)